Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardia Inc.

Division of BioCardia Inc./BioCardia
www.cardiainc.com

Latest From Cardia Inc.

J&J Enters LAA Closure Market In Earnest With Coherex Buy

J&J's Biosense Webster heart-rhythm device unit has acquired privately held partner Coherex Medical, solidifying its stake in the left atrial appendage closure market that Boston Scientific currently leads.

Medical Device Europe

Who's Next? Emerging LAA Closure Devices

As first-to-market in the US with a transcatheter left atrial appendage closure device, Boston Scientific has blazed a regulatory and reimbursement trail for other companies in this space and opened up a potentially billion-dollar-plus market. In this second part of our two-part series on LAAC devices, Medtech Insight reports on other companies with current and emerging LAAC devices and looks at how close they are to bringing their technology to the US market.

Medical Device Innovation

LAA Closure Devices At The Tipping Point

Since the FDA approval of Boston Scientific Corp.'s WATCHMAN device in March, the US market for left atrial appendage closure devices has reached a tipping point. With first-to-market advantage in the US, and a four- to five-year lead on the competition in bringing a LAAC device to the US market, BSX is well positioned to gain a strong foothold in this potentially billion dollar plus market; however, several factors will dictate market adoption of these devices in the US, including reimbursement, clinical efficacy, cost and ease of use.

Medical Device Innovation

Recent Developments in PFO Closure

The patent foramen ovale closure market has continued to mature in 2009, with the latest round of developments reported at the 2009 Transcatheter Cardiovascular Therapeutics meeting, recently held in San Francisco. Over 60 presentations related to PFO closure or atrial septal defect closure were presented at TCT this year, more than double the amount of PFO-related talks presented in 2008.
Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • BioCardia Inc.
  • Cardia Inc.
  • Senior Management
  • Joseph Marino, Pres.
  • Contact Info
  • Cardia Inc.
    13770 Fontier Court
    Burnsville, MN 55337
    USA
UsernamePublicRestriction

Register